ABSTRACT -This article focuses on 2 clinical case re p o rts of narcoleptic patients who experienced an absence of excessive sleepiness during treatment of other illnesses with 40 mg daily intake of prednisone.
Narcolepsy is characterized by excessive daytime sleep and cataplexy. Sleep paralysis, hypnagogic hallucinations and sleep fragmentation can be added to this clinical picture 1 , 2 . Narcolepsy involves an unknown physiopathology but with a known association with the HLA DQB1*0602 allele 3 . This would stre n g t hen the hypothesis of a genetic origin. Other physiopathological hypotheses derive from the environment, infections and the immunological system. Abn o rmalities in the neurotransmission of hypocre t i n w e re recently described in narc o l e p t i c s 4 . Hypocre t i n is a neuropeptide synthesized by neurons whose cell bodies are located in the lateral hypothalamus. One of its functions is to modulate wakefulness. The association of hypocretin to dopaminergic pathways in f rontal brain and noradre n e rgics pathways in the brain stem is well established. The smaller concentration of hypocretin in cerebral spinal fluid (CSF) has only been characterized in narcoleptics with catap l e x y 5 . In an immunohystochemical study, a re d u ction in the quantity of hypocre t i n e rgic cells of the lateral hypothalamus was observed in patients with c a t a p l e x y 6 . This observation was made following autopsy.
Patients with frequent outbursts of cataplexy highlight a greater prevalence of the HLA DQB1*0602 allele along with a marked diminution of hypocretin in CSF when compared with patients with rare , atypical or absence of cataplexy.
A reduction in tumor necrosis factor (TNF) and interleukin-6 (IL-6) levels were described in narc o l e ptic patients and in one of our studies 7 , we noticed a reduction in subpopulations of T CD4 and B-lymplocytes in narcoleptic patients presenting frequent cataplectic attacks 8 . I m m u n o s u p p ressants have not normally been used when treating narc o l e p s y. One single case was found c o n c e rning a narcoleptic boy who had been tre a t e d with corticoid pulse therapy in the initial stages of the disease 9 . This paper set out to describe the re c o v e ry fro m daytime somnolence associated to narcolepsy in two patients who took prednisone for bronchitis and ulcerative retocolites re s p e c t i v e l y. Patients gave writ-ten consent to participate in studies concerning narcolepsy (UNIFESP-EPM 1139/03) and consented to the publication of their case report.
CASES
Case 1 -A 22-year old m ale, was diagnosed with narcolepsy in August 2004. He presented excessive daytime somnolence, frequent cataplexy and hypnagogic hallucinations. The initial symptoms started when he was 13. E p w o rth Sleep Scale was 15. HLA DQB1*0602 was positive. Polysomnographic re c o rdings showed no specific alterations and in the MSLT test we noted a sleep latency of 4 minutes with 2 episodes of REM sleep. Our patient received metilfenidate (20 mg/day) and immipramine (25 mg/day) for 6 months with significative diminution of the symptoms. P rednisone (40 mg/day) was initiated for treatment of i n f l a m m a t o ry intestinal disease and af ter a week's tre a tment, the patient highlighted less somnolence and absence of cataplectic attacks. The patient ceased taking m edication for narcolepsy on his own accord. After several months he was apparently free from any narcoleptic symptoms but continued to use prednisone. 
DISCUSSION
Our understanding of narcolepsy has impro v e d in recent years. The greater prevalence of the HLA DQB1*0602 allele in patients with narcolepsy and cataplexy is well known 3 , 4 . The discovery of hypocretin and its reduction through cell loss in the lateral hypothalamus in patients with frequent cataplexy is one possible explanation for the main clinical symptoms in narcolepsy 4 . C u rre n t l y, the treatment of narcolpesy is based only on symptomatological control. Given that modafinil is not an authorized medication in Brazil, we used only metilfenidate to control the daytime somnolence and administered tryciclics to minimise cataplectic attacks. Curre n t l y, there is no treatment that can halt the evolution of the disease, as the exact physiopathological mechanism is unknown 6 .
Analysing recent papers on narc o l e p s y, we noted a single re p o rt of corticoid use 9 . The discussion of that case re p o rt claimed that the possible immunological auto-agression occurs only during the initial stages of the disease.
For our patients, two hypotheses can be form ulated to explain the changes in their narcoleptic outlook. Corticoides can reduce somnolence through an a rousing and independent effect without any re l ation to the mechanisms underpinning narc o l e p s y. Some interactions of the hypothalamic-pituitary -a d renal (HPA) axis and sleep are known 1 0 . There is also a possible impact on physiopathological mechanisms of narcolepsy leading to a reduction of symptoms.
We believe that these case re p o rts can add to the debat surrounding pathophysiological mechanisms involving narcolepsy.
